OBJECTIVE: To examine associations of anti-cyclic citrullinated peptide (aCCP) antibody and rheumatoid factor (RF) concentrations with future disease activity in men with rheumatoid arthritis (RA). METHODS: Outcome measures were examined in male US veterans with RA and included (1) proportion of observations in remission (disease activity score (DAS28) < or =2.6); (2) remission for > or =3 consecutive months; and (3) area under the curve (AUC) for DAS28. The associations of autoantibody concentration (per 100 unit increments) with outcomes were examined using multivariate regression. RESULTS: 826 men with RA were included in the analysis; the mean (SD) age was 65 (10.5) years and follow-up was for 2.6 (1.3) years. Most were aCCP (75%) and RF (80%) positive. After multivariate adjustment, aCCP (OR 0.93; 95% CI 0.89 to 0.96) and RF concentrations (OR 0.92; 95% CI 0.90 to 0.94) were associated with a lower odds of remission, a lower proportion of observation in remission (p=0.017 and p=0.002, respectively) and greater AUC DAS28 (p=0.092 and p=0.007, respectively). Among patients with discordant autoantibody status, higher concentrations of both aCCP and RF trended towards an inverse association with remission (OR 0.93; 95% CI 0.83 to 1.05 and OR 0.80; 95% CI 0.59 to 1.10, respectively). CONCLUSIONS: Higher aCCP concentrations (particularly in RF-positive patients) are associated with increased disease activity in US veterans with RA, indicating that aCCP concentration is predictive of future disease outcomes in men.
OBJECTIVE: To examine associations of anti-cyclic citrullinated peptide (aCCP) antibody and rheumatoid factor (RF) concentrations with future disease activity in men with rheumatoid arthritis (RA). METHODS: Outcome measures were examined in male US veterans with RA and included (1) proportion of observations in remission (disease activity score (DAS28) < or =2.6); (2) remission for > or =3 consecutive months; and (3) area under the curve (AUC) for DAS28. The associations of autoantibody concentration (per 100 unit increments) with outcomes were examined using multivariate regression. RESULTS: 826 men with RA were included in the analysis; the mean (SD) age was 65 (10.5) years and follow-up was for 2.6 (1.3) years. Most were aCCP (75%) and RF (80%) positive. After multivariate adjustment, aCCP (OR 0.93; 95% CI 0.89 to 0.96) and RF concentrations (OR 0.92; 95% CI 0.90 to 0.94) were associated with a lower odds of remission, a lower proportion of observation in remission (p=0.017 and p=0.002, respectively) and greater AUC DAS28 (p=0.092 and p=0.007, respectively). Among patients with discordant autoantibody status, higher concentrations of both aCCP and RF trended towards an inverse association with remission (OR 0.93; 95% CI 0.83 to 1.05 and OR 0.80; 95% CI 0.59 to 1.10, respectively). CONCLUSIONS: Higher aCCP concentrations (particularly in RF-positive patients) are associated with increased disease activity in US veterans with RA, indicating that aCCP concentration is predictive of future disease outcomes in men.
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: Tuulikki Sokka; Sergio Toloza; Maurizio Cutolo; Hannu Kautiainen; Heidi Makinen; Feride Gogus; Vlado Skakic; Humeira Badsha; Tõnu Peets; Asta Baranauskaite; Pál Géher; Ilona Ujfalussy; Fotini N Skopouli; Maria Mavrommati; Rieke Alten; Christof Pohl; Jean Sibilia; Andrea Stancati; Fausto Salaffi; Wojciech Romanowski; Danuta Zarowny-Wierzbinska; Dan Henrohn; Barry Bresnihan; Patricia Minnock; Lene Surland Knudsen; Johannes Wg Jacobs; Jaime Calvo-Alen; Juris Lazovskis; Geraldo da Rocha Castelar Pinheiro; Dmitry Karateev; Daina Andersone; Sylejman Rexhepi; Yusuf Yazici; Theodore Pincus Journal: Arthritis Res Ther Date: 2009-01-14 Impact factor: 5.156
Authors: Jeremy Sokolove; Dannette S Johnson; Lauren J Lahey; Catriona A Wagner; Danye Cheng; Geoffrey M Thiele; Kaleb Michaud; Harlan Sayles; Andreas M Reimold; Liron Caplan; Grant W Cannon; Gail Kerr; Ted R Mikuls; William H Robinson Journal: Arthritis Rheumatol Date: 2014-04 Impact factor: 10.995
Authors: Ted R Mikuls; Jeffrey B Payne; Fang Yu; Geoffrey M Thiele; Richard J Reynolds; Grant W Cannon; Jeffrey Markt; David McGowan; Gail S Kerr; Robert S Redman; Andreas Reimold; Garth Griffiths; Mark Beatty; Shawneen M Gonzalez; Debra A Bergman; Bartlett C Hamilton; Alan R Erickson; Jeremy Sokolove; William H Robinson; Clay Walker; Fatiha Chandad; James R O'Dell Journal: Arthritis Rheumatol Date: 2014-05 Impact factor: 10.995
Authors: Nishant Dwivedi; Jagriti Upadhyay; Indira Neeli; Salar Khan; Debendra Pattanaik; Linda Myers; Kyriakos A Kirou; Bernhard Hellmich; Bryan Knuckley; Paul R Thompson; Mary K Crow; Ted R Mikuls; Elena Csernok; Marko Radic Journal: Arthritis Rheum Date: 2011-10-27
Authors: P M Maloley; B R England; H Sayles; G M Thiele; K Michaud; J Sokolove; G W Cannon; A M Reimold; G S Kerr; J F Baker; L Caplan; A J Case; T R Mikuls Journal: Semin Arthritis Rheum Date: 2019-02-08 Impact factor: 5.532
Authors: Ted R Mikuls; Brian T Fay; Kaleb Michaud; Harlan Sayles; Geoffrey M Thiele; Liron Caplan; Dannette Johnson; John S Richards; Gail S Kerr; Grant W Cannon; Andreas Reimold Journal: Rheumatology (Oxford) Date: 2010-07-21 Impact factor: 7.580
Authors: Andrew Chiou; Bryant R England; Harlan Sayles; Geoffrey M Thiele; Michael J Duryee; Joshua F Baker; Namrata Singh; Grant W Cannon; Gail S Kerr; Andreas Reimold; Angelo Gaffo; Ted R Mikuls Journal: Arthritis Care Res (Hoboken) Date: 2020-06-07 Impact factor: 4.794
Authors: Pascale Schwab; Harlan Sayles; Debra Bergman; Grant W Cannon; Kaleb Michaud; Ted R Mikuls; Jennifer Barton Journal: Arthritis Care Res (Hoboken) Date: 2017-05-09 Impact factor: 4.794